Skip to Main Content

Paper Details

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
medRxiv
0
2022
B.1.1.529, BA, CD20, COVID, COVID-19, MS, Omicron, Participants, People, S1PR, SARS, SARS-, SARS-CoV-2, Spike antigen, T cell, WA1, anti-, anti-CD20, coronavirus disease, multiple sclerosis, participants, people, severe, severe acute respiratory syndrome coronavirus 2, sphingosine, sphingosine 1-phosphate, sphingosine 1-phosphate receptor, sphingosine receptor-1

Datasets

Release 1.2